Massachusetts Biotechnology Council's MASS Opportunities - Mintz Levin Sponsorship
Boston, MA
10/28/2003
Mintz Levin is sponsoring Massachusetts Biotechnology Council's MASS Opportunities conference October 27-28, 2003, in Boston. Jeffrey Wiesen will moderate a roundtable discussion entitled, "What is This Year's Biotechnology Fashion? What's Hot, What's Not!" which will discuss the latest "fashions" in biotechnology.
Since the birth of the industry in the 1970s, Mintz Levin has been representing biotechnology companies in all aspects of their businesses, and today the firm has one of the largest biotechnology practices in the country. The firm assists clients with a broad range of legal and business issues and transactions, including organization, private and public offerings of securities, creation of "off balance sheet" financing vehicles, acquisitions of technology, intellectual property, joint ventures and strategic partnerships, mergers and acquisitions, leasing and construction of R&D and manufacturing facilities, product development, and regulatory matters.
Jeff Wiesen is a member in the Mintz Levin?s Boston office, Chairman of the Biotechnology Practice, and a member of the firm?s Policy Committee. He served as President and Chief Executive Officer from 1994-1996. He has been an active participant and leader in the Biotechnology Industry since its inception in the late ?70s. He was involved in the formation of some of the earliest companies, and the structuring and negotiation of some of the industry?s earliest strategic alliances, venture financings and public offerings and has led Mintz Levin?s Biotechnology Group to become one of the largest and best known in the country. His clients range in size from newly-formed start-up ventures to substantial public companies. He assists these companies with a range of transactions, both domestic and international, including private and public finance, mergers and acquisitions, strategic alliances, joint ventures, technology transfer and cross-transfer agreements, as well as general legal advice, and has successfully structured, coordinated and negotiated technology-based transactions with numerous world-wide pharmaceutical and chemical companies. His clients often think of him as an extra member of the executive management team.
